Labcorp (LH) Beats Q2 Earnings and Revenue Estimates
Labcorp (LH) came out with quarterly earnings of $3.94 per share, beating the Zacks Consensus Estimate of $3.78 per share. This compares to earnings of $3.42 per share a year ago.
Labcorp beats Q2 profit and revenue estimates on demand for health tests
Labcorp beat Wall Street expectations for second-quarter profit and revenue on Thursday on strong demand for its diagnostic tests, and raised its sales growth forecast for the year.
Labcorp (LH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Labcorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's How Labcorp (LH) is Placed Ahead of Q2 Earnings Release
Labcorp's (LH) second-quarter 2024 performance is expected to reflect the robust execution of strategic priorities and solid business performances.
Here's Why Labcorp (LH) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is It the Right Time to Hold Labcorp (LH) in Your Portfolio?
Labcorp's (LH) concentrated development in high-growth areas and strategic partnerships appear encouraging.
Why Labcorp (LH) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Foundations Investment Advisors LLC Buys Shares of 1,214 Laboratory Co. of America Holdings (NYSE:LH)
Foundations Investment Advisors LLC bought a new position in shares of Laboratory Co. of America Holdings (NYSE:LH – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 1,214 shares of the medical research company’s stock, valued at approximately $272,000. Other hedge funds have also recently bought and sold shares of the company. Provence Wealth Management Group purchased a new stake in shares of Laboratory Co. of America during the third quarter worth $29,000. Mendota Financial Group LLC acquired a new stake in Laboratory Co. of America in the 4th quarter valued at about $29,000. Bruce G. Allen Investments LLC acquired a new position in shares of Laboratory Co. of America during the fourth quarter worth about $60,000. Disciplined Equity Management Inc. purchased a new stake in shares of Laboratory Co. of America during the fourth quarter worth approximately $68,000. Finally, Oakworth Capital Inc. raised its holdings in Laboratory Co. of America by 48.1% in the fourth quarter. Oakworth Capital Inc. now owns 308 shares of the medical research company’s stock valued at $70,000 after acquiring an additional 100 shares in the last quarter. Institutional investors and hedge funds own 95.94% of the company’s stock. Wall Street Analysts Forecast Growth LH has been the topic of several recent analyst reports. Argus raised Laboratory Co. of America from a “hold” rating to a “buy” rating and set a $250.00 target price on the stock in a report on Monday, March 25th. TheStreet lowered Laboratory Co. of America from a “b-” rating to a “c+” rating in a research report on Thursday, February 15th. Evercore ISI started coverage on Laboratory Co. of America in a report on Friday, February 9th. They issued an “in-line” rating and a $240.00 price target for the company. Barclays cut their price objective on shares of Laboratory Co. of America from $234.00 to $213.00 and set an “equal weight” rating on the stock in a report on Friday, April 26th. Finally, Robert W. Baird lowered their target price on shares of Laboratory Co. of America from $255.00 to $244.00 and set an “outperform” rating for the company in a report on Friday, April 26th. Four equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $243.14. Read Our Latest Research Report on LH Laboratory Co. of America Stock Down 1.2 % Shares of NYSE:LH opened at $210.59 on Monday. The company has a market cap of $17.75 billion, a price-to-earnings ratio of 42.37, a PEG ratio of 1.58 and a beta of 1.02. Laboratory Co. of America Holdings has a fifty-two week low of $174.20 and a fifty-two week high of $234.09. The firm’s 50-day simple moving average is $208.28 and its 200-day simple moving average is $215.41. The company has a quick ratio of 0.76, a current ratio of 0.88 and a debt-to-equity ratio of 0.39. Laboratory Co. of America (NYSE:LH – Get Free Report) last released its earnings results on Thursday, April 25th. The medical research company reported $3.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.48 by $0.20. The company had revenue of $3.18 billion for the quarter, compared to analysts’ expectations of $3.12 billion. Laboratory Co. of America had a return on equity of 14.68% and a net margin of 3.52%. The firm’s quarterly revenue was up 4.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.82 EPS. As a group, equities research analysts predict that Laboratory Co. of America Holdings will post 14.87 earnings per share for the current year. Laboratory Co. of America Announces Dividend The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 12th. Stockholders of record on Tuesday, May 28th will be paid a dividend of $0.72 per share. The ex-dividend date is Friday, May 24th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.37%. Laboratory Co. of America’s dividend payout ratio (DPR) is presently 57.95%. Insider Activity In other Laboratory Co. of America news, EVP Jonathan P. Divincenzo sold 500 shares of the company’s stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $215.49, for a total transaction of $107,745.00. Following the transaction, the executive vice president now directly owns 3,401 shares in the company, valued at $732,881.49. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, EVP Jonathan P. Divincenzo sold 500 shares of the business’s stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $215.49, for a total value of $107,745.00. Following the sale, the executive vice president now directly owns 3,401 shares in the company, valued at approximately $732,881.49. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CAO Peter J. Wilkinson sold 2,439 shares of the firm’s stock in a transaction dated Monday, April 29th. The shares were sold at an average price of $204.33, for a total transaction of $498,360.87. Following the transaction, the chief accounting officer now owns 2,087 shares of the company’s stock, valued at $426,436.71. The disclosure for this sale can be found here. Insiders sold 58,748 shares of company stock worth $12,670,956 in the last 90 days. 0.85% of the stock is currently owned by corporate insiders. Laboratory Co. of America Company Profile (Free Report) Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS). See Also Five stocks we like better than Laboratory Co. of America 3 Natural Gas Stocks That Offer Great Dividend Yields Canada Goose Flies Higher Driven By DTC Growth Dividend Screener: How to Evaluate Dividend Stocks Before Buying CVS Health Stock Has a Silver Lining Called Value Conference Calls and Individual Investors Magnificent 7 Still Magnificent as the Halfway Mark Approaches?
Labcorp (LH) to Assess Preeclampsia Risk With New Test
Labcorp's (LH) new first-trimester test is the latest addition to its dedication to improving women's health.
